Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 1/2015

Open Access 01-12-2015 | Review article

Does this patient have pheochromocytoma? A systematic review of clinical signs and symptoms

Authors: M. Pourian, Davani B. Mostafazadeh, A. Soltani

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2015

Login to get access

Abstract

Context

Pheochromocytoma is a rare disease but with high mortality if it is not being diagnosed early. Several biochemical tests with high accuracy have been obtained, but the clinical threshold for request of these tests is not determined clearly.

Objectives

To determine the Likelihood Ratios of clinical symptoms and signs in diagnosing pheochromocytoma. And also meta-analysis of their sensitivity in this disease.

Data sources

MEDLINE was searched for relevant English-language articles dated 1960 to February 2014. Bibliographies were searched to find additional articles.

Study selection

We included original studies describing the sensitivity and/or likelihood ratios of signs and symptoms in clinical suspicion of pheochromocytoma. Their method of diagnosis should have been based on pathology. We excluded specific subtypes or syndromes related to pheochromocytoma, or specific ages or gender. Also we excluded studies before 1993 (JNC5) which no definition of hypertension was presented. 37 articles were chosen finally.

Data extraction

Two authors reviewed data from articles independently and gave discrepancies to third author for decision. The aim was extraction of raw numbers of patients having defined signs or symptoms, and draw 2 × 2 tables if data available. We meta-analyzed sensitivities by Statsdirect and Likelihood Ratios by Meta-disc soft wares. Because our data was heterogeneous based on I2 > 50 % (except negative Likelihood ratio of hypertension), we used random effect model for doing meta-analysis. We checked publication bias by drawing Funnel plot for each sign/symptom, and also Egger test.

Data synthesis

The most prevalent signs and symptoms reported were hypertension (pooled sensitivity of 80.7 %), headache (pooled sensitivity of 60.4 %), palpitation (pooled sensitivity of 59.3 %) and diaphoresis (pooled sensitivity of 52.4 %). The definition of orthostatic hypotension was different among studies. The sensitivity was 23–50 %.
Paroxysmal hypertension, chest pain, flushing, and weakness were the signs/symptoms which had publication bias based on Funnel plot and Egger test (P value < 0.05). Seven of the articles had control group, and could be used for calculating LR of signs/symptoms. Diaphoresis (LR+ 2.2, LR- 0.45), Palpitation (LR+ 1.9, LR- 0.52) and headache (LR+ 1.6, LR- 0.24) were significant symptoms in clinical diagnosis of pheochromocytoma. Other signs and symptoms had been reported in only one study and could not have been meta-analyzed. Classic triad of headache, palpitation and diaphoresis in hypertensive patients had the LR+ 6.312 (95 % CI 0.217–183.217) and LR- 0.139 (95 % CI 0.059–0.331). Surprisingly, hypertension was not important in clinical suspicion of pheochromocytoma, and even normotension increased the probability of the disease.

Conclusions

By available data, there is no single clinical finding that has significant value in diagnosis or excluding pheochromocytoma. Combination of certain symptoms, signs and para-clinical exams is more valuable for physicians. Further studies should be done, to specify the value of clinical findings. Until that time the process of diagnosis will be based on clinical suspicion and lab tests followed by related imaging.
Footnotes
1
This strategy was selected based on the “search strategy for the rational clinical examination- David L. Simel, 1995”.
 
Literature
1.
go back to reference Adler JT et al. Pheochromocytoma: Current approaches and future directions. Oncologist. 2008;13:779–93.CrossRefPubMed Adler JT et al. Pheochromocytoma: Current approaches and future directions. Oncologist. 2008;13:779–93.CrossRefPubMed
3.
go back to reference Lo CY et al. Adrenal Pheochromocytoma remains a frequently overlooked diagnosis. Am J Surg. 2000;179:212–5.CrossRefPubMed Lo CY et al. Adrenal Pheochromocytoma remains a frequently overlooked diagnosis. Am J Surg. 2000;179:212–5.CrossRefPubMed
5.
go back to reference McClellan M, Walther á HR, Keiser W. Marston Linehan Pheochromocytoma: evaluation, diagnosis, and treatment. World J Urol. 1999;17:35–9.CrossRef McClellan M, Walther á HR, Keiser W. Marston Linehan Pheochromocytoma: evaluation, diagnosis, and treatment. World J Urol. 1999;17:35–9.CrossRef
6.
go back to reference Mannelli M, Ianni L, Cilotti A, Conti A. Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol. 1999;141(6):619.CrossRefPubMed Mannelli M, Ianni L, Cilotti A, Conti A. Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol. 1999;141(6):619.CrossRefPubMed
7.
go back to reference Favia G, Lumachi F, Polistina F, D’Amico DF. Pheochromocytoma, a rare cause of hypertension: long-term follow-up of 55 surgically treated patients. World J Surg. 1998;22(7):689–93. discussion 694.CrossRefPubMed Favia G, Lumachi F, Polistina F, D’Amico DF. Pheochromocytoma, a rare cause of hypertension: long-term follow-up of 55 surgically treated patients. World J Surg. 1998;22(7):689–93. discussion 694.CrossRefPubMed
8.
go back to reference Stenström G, Ernest I, Tisell LE. Long-term results in 64 patients operated upon for pheochromocytoma. Acta Med Scand. 1988;223(4):345–52.CrossRefPubMed Stenström G, Ernest I, Tisell LE. Long-term results in 64 patients operated upon for pheochromocytoma. Acta Med Scand. 1988;223(4):345–52.CrossRefPubMed
9.
go back to reference Sutton MG, Sheps SG, Lie JT. Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. Mayo Clin Proc. 1981;56(6):354–60.PubMed Sutton MG, Sheps SG, Lie JT. Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. Mayo Clin Proc. 1981;56(6):354–60.PubMed
10.
go back to reference Benowitz NL. Pheochromocytoma-Recent advances in diagnosis and treatment [Medical Staff Conference]. West J Med. 1988;148:561–7.PubMed Benowitz NL. Pheochromocytoma-Recent advances in diagnosis and treatment [Medical Staff Conference]. West J Med. 1988;148:561–7.PubMed
11.
go back to reference Zelinka T, Eisenhofer G, Pacak K. Pheochromocytoma as a catecholamine producing tumor: Implications for clinical practice. Stress. 2007;10(2):195–203.CrossRefPubMed Zelinka T, Eisenhofer G, Pacak K. Pheochromocytoma as a catecholamine producing tumor: Implications for clinical practice. Stress. 2007;10(2):195–203.CrossRefPubMed
12.
go back to reference Plouin PF, Degoulet P, Tugayé A, Ducrocq MB, Ménard J. [Screening for phaeochromocytoma: in which hypertensive patients? A semiological study of 2585 patients, including 11 with phaeochromocytoma (author’s transl)]. Nouv Press Med. 1981;10(11):869–72. French. Plouin PF, Degoulet P, Tugayé A, Ducrocq MB, Ménard J. [Screening for phaeochromocytoma: in which hypertensive patients? A semiological study of 2585 patients, including 11 with phaeochromocytoma (author’s transl)]. Nouv Press Med. 1981;10(11):869–72. French.
13.
go back to reference Werbel SS, Ober KP. Pheochromocytoma. Update on diagnosis, localization, and management. Med Clin North Am. 1995;79(1):131–53.CrossRefPubMed Werbel SS, Ober KP. Pheochromocytoma. Update on diagnosis, localization, and management. Med Clin North Am. 1995;79(1):131–53.CrossRefPubMed
14.
go back to reference Fauci, Braunwald, Kasper, Hauser, Longo, Jameson, Loscalzo. Harrison’s principles of internal medicine. 17th edition. Part 15. Chapter 337. p 2269. Fauci, Braunwald, Kasper, Hauser, Longo, Jameson, Loscalzo. Harrison’s principles of internal medicine. 17th edition. Part 15. Chapter 337. p 2269.
15.
go back to reference Lance JW, Hinterberger H. Symptoms of pheochromocytoma, with particular reference to headache, correlated with catecholamine production. Arch Neurol. 1976;33(4):281–8.CrossRefPubMed Lance JW, Hinterberger H. Symptoms of pheochromocytoma, with particular reference to headache, correlated with catecholamine production. Arch Neurol. 1976;33(4):281–8.CrossRefPubMed
16.
go back to reference Stein PP, Black HR. A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one institution’s experience. Medicine (Baltimore). 1991;70(1):46–66.CrossRef Stein PP, Black HR. A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one institution’s experience. Medicine (Baltimore). 1991;70(1):46–66.CrossRef
17.
go back to reference Black HR, Bursten SL. A clinical scoring system for detection of patients with pheochromocytomas. Yale J Biol Med. 1984;57(3):259–72.PubMedPubMedCentral Black HR, Bursten SL. A clinical scoring system for detection of patients with pheochromocytomas. Yale J Biol Med. 1984;57(3):259–72.PubMedPubMedCentral
18.
go back to reference The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154–83. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154–83.
19.
go back to reference Lai EW, Perera SM, Havekes B, Timmers HJ, Brouwers FM, McElroy B, et al. Gender-related differences in the clinical presentation of malignant and benign pheochromocytoma. Endocrine. 2008;34(1–3):96–100. Epub 2008 Nov 4.CrossRefPubMed Lai EW, Perera SM, Havekes B, Timmers HJ, Brouwers FM, McElroy B, et al. Gender-related differences in the clinical presentation of malignant and benign pheochromocytoma. Endocrine. 2008;34(1–3):96–100. Epub 2008 Nov 4.CrossRefPubMed
20.
go back to reference Plouin PF, Chatellier G, Rougeot MA, Duclos JM, Pagny JY, Corvol P, et al. Recent developments in pheochromocytoma diagnosis and imaging. Adv Nephrol Necker Hosp. 1988;17:275–86. Review.PubMed Plouin PF, Chatellier G, Rougeot MA, Duclos JM, Pagny JY, Corvol P, et al. Recent developments in pheochromocytoma diagnosis and imaging. Adv Nephrol Necker Hosp. 1988;17:275–86. Review.PubMed
21.
go back to reference Patócs A, Karádi E, Tóth M, Varga I, Szücs N, Balogh K, et al. Clinical and biochemical features of sporadic and hereditary phaeochromocytomas: an analysis of 41 cases investigated in a single endocrine centre. Eur J Cancer Prev. 2004;13(5):403–9.CrossRefPubMed Patócs A, Karádi E, Tóth M, Varga I, Szücs N, Balogh K, et al. Clinical and biochemical features of sporadic and hereditary phaeochromocytomas: an analysis of 41 cases investigated in a single endocrine centre. Eur J Cancer Prev. 2004;13(5):403–9.CrossRefPubMed
22.
go back to reference Hernandez FC, Sánchez M, Alvarez A, Díaz J, Pascual R, Pérez M, et al. A five-year report on experience in the detection of pheochromocytoma. Clin Biochem. 2000;33(8):649–55.CrossRefPubMed Hernandez FC, Sánchez M, Alvarez A, Díaz J, Pascual R, Pérez M, et al. A five-year report on experience in the detection of pheochromocytoma. Clin Biochem. 2000;33(8):649–55.CrossRefPubMed
23.
go back to reference Václavík J, Stejskal D, Lacnák B, Lazárová M, Jedelský L, Kadalová L, et al. Free plasma metanephrines as a screening test for pheochromocytoma in low-risk patients. J Hypertens. 2007;25(7):1427–31.CrossRefPubMed Václavík J, Stejskal D, Lacnák B, Lazárová M, Jedelský L, Kadalová L, et al. Free plasma metanephrines as a screening test for pheochromocytoma in low-risk patients. J Hypertens. 2007;25(7):1427–31.CrossRefPubMed
24.
go back to reference Loh KC, Shlossberg AH, Abbott EC, Salisbury SR, Tan MH. Pheochromocytoma: a ten-year survey. QJM. 1997;90(1):51–60.CrossRefPubMed Loh KC, Shlossberg AH, Abbott EC, Salisbury SR, Tan MH. Pheochromocytoma: a ten-year survey. QJM. 1997;90(1):51–60.CrossRefPubMed
25.
go back to reference Proye CA, Vix M, Jansson S, Tisell LE, Dralle H, Hiller W. “The pheochromocytoma”: a benign, intra-adrenal, hypertensive, sporadic unilateral tumor. Does it exist? World J Surg. 1994;18(4):467–72.CrossRefPubMed Proye CA, Vix M, Jansson S, Tisell LE, Dralle H, Hiller W. “The pheochromocytoma”: a benign, intra-adrenal, hypertensive, sporadic unilateral tumor. Does it exist? World J Surg. 1994;18(4):467–72.CrossRefPubMed
26.
go back to reference Plouin PF, Chatellier G, Fofol I, Corvol P. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension. 1997;29(5):1133–9.CrossRefPubMed Plouin PF, Chatellier G, Fofol I, Corvol P. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension. 1997;29(5):1133–9.CrossRefPubMed
27.
go back to reference Perry RR, Keiser HR, Norton JA, Wall RT, Robertson CN, Travis W, et al. Surgical management of pheochromocytoma with the use of metyrosine. Ann Surg. 1990;212(5):621–8.CrossRefPubMedPubMedCentral Perry RR, Keiser HR, Norton JA, Wall RT, Robertson CN, Travis W, et al. Surgical management of pheochromocytoma with the use of metyrosine. Ann Surg. 1990;212(5):621–8.CrossRefPubMedPubMedCentral
28.
go back to reference O’Halloran T, McGreal G, McDermott E, O’Higgins N. 47 years of phaeochromocytomas. Ir Med J. 2001;94(7):200–3.PubMed O’Halloran T, McGreal G, McDermott E, O’Higgins N. 47 years of phaeochromocytomas. Ir Med J. 2001;94(7):200–3.PubMed
29.
go back to reference Aguiló F, Tamayo N, Vázquez-Quintana E, Rabell V, Haddock L, Allende M, et al. Pheochromocytoma: a twenty year experience at the University Hospital. P R Health Sci J. 1991;10(3):135–42. Review. Erratum in: P R Health Sci J 1992 Apr;11(1):6.PubMed Aguiló F, Tamayo N, Vázquez-Quintana E, Rabell V, Haddock L, Allende M, et al. Pheochromocytoma: a twenty year experience at the University Hospital. P R Health Sci J. 1991;10(3):135–42. Review. Erratum in: P R Health Sci J 1992 Apr;11(1):6.PubMed
30.
go back to reference Thomas JE, Rooke ED, Kvale WF. The neurologist’s experience with pheochromocytoma. A review of 100 cases. JAMA. 1966;197(10):754–8.CrossRefPubMed Thomas JE, Rooke ED, Kvale WF. The neurologist’s experience with pheochromocytoma. A review of 100 cases. JAMA. 1966;197(10):754–8.CrossRefPubMed
31.
go back to reference Kopetschke R, Slisko M, Kilisli A, Tuschy U, Wallaschofski H, Fassnacht M, et al. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol. 2009;161(2):355–61. Epub 2009 Jun 4.CrossRefPubMed Kopetschke R, Slisko M, Kilisli A, Tuschy U, Wallaschofski H, Fassnacht M, et al. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol. 2009;161(2):355–61. Epub 2009 Jun 4.CrossRefPubMed
32.
go back to reference Charles C, Grell GA, Fletcher PR, Hanchard B. A clinico-pathological study on pheochromocytoma at the University Hospital of the West Indies. West Indian Med J. 1984;33(4):241–5.PubMed Charles C, Grell GA, Fletcher PR, Hanchard B. A clinico-pathological study on pheochromocytoma at the University Hospital of the West Indies. West Indian Med J. 1984;33(4):241–5.PubMed
33.
34.
go back to reference Yau JS, Li JK, Tam VH, Fung LM, Yeung CK, Chan KW, et al. Phaeochromocytoma in the Hong Kong Chinese population. Hong Kong Med J. 2010;16(4):252–6.PubMed Yau JS, Li JK, Tam VH, Fung LM, Yeung CK, Chan KW, et al. Phaeochromocytoma in the Hong Kong Chinese population. Hong Kong Med J. 2010;16(4):252–6.PubMed
35.
go back to reference van Duinen N, Steenvoorden D, Bonsing BA, Vuyk J, Vriends AH, Jansen JC, et al. Pheochromocytomas detected by biochemical screening in predisposed subjects are associated with lower prevalence of clinical and biochemical manifestations and smaller tumors than pheochromocytomas detected by signs and symptoms. Eur J Endocrinol. 2010;163(1):121–7. Epub 2010 Apr 30.CrossRefPubMed van Duinen N, Steenvoorden D, Bonsing BA, Vuyk J, Vriends AH, Jansen JC, et al. Pheochromocytomas detected by biochemical screening in predisposed subjects are associated with lower prevalence of clinical and biochemical manifestations and smaller tumors than pheochromocytomas detected by signs and symptoms. Eur J Endocrinol. 2010;163(1):121–7. Epub 2010 Apr 30.CrossRefPubMed
36.
go back to reference Glodny B, Winde G, Herwig R, Meier A, Kühle C, Cromme S, et al. Clinical differences between benign and malignant pheochromocytomas. Endocr J. 2001;48(2):151–9.CrossRefPubMed Glodny B, Winde G, Herwig R, Meier A, Kühle C, Cromme S, et al. Clinical differences between benign and malignant pheochromocytomas. Endocr J. 2001;48(2):151–9.CrossRefPubMed
37.
go back to reference Modlin IM, Farndon JR, Shepherd A, Johnston ID, Kennedy TL, Montgomery DA, et al. Pheochromocytomas in 72 patients: clinical and diagnostic features, treatment and long term results. Br J Surg. 1979;66(7):456–65.CrossRefPubMed Modlin IM, Farndon JR, Shepherd A, Johnston ID, Kennedy TL, Montgomery DA, et al. Pheochromocytomas in 72 patients: clinical and diagnostic features, treatment and long term results. Br J Surg. 1979;66(7):456–65.CrossRefPubMed
38.
go back to reference Ross EJ, Griffith DNW. The clinical presentation of pheochromocytoma. QJM. 1989;71(266):485–96.PubMed Ross EJ, Griffith DNW. The clinical presentation of pheochromocytoma. QJM. 1989;71(266):485–96.PubMed
39.
go back to reference Niemann U, Hiller W, Behrend M. 25 years experience of the surgical treatment of phaeochromocytoma. Eur J Surg. 2002;168(12):716–9.CrossRefPubMed Niemann U, Hiller W, Behrend M. 25 years experience of the surgical treatment of phaeochromocytoma. Eur J Surg. 2002;168(12):716–9.CrossRefPubMed
40.
go back to reference Noshiro T, Shimizu K, Watanabe T, Akama H, Shibukawa S, Miura W, et al. Changes in clinical features and long-term prognosis in patients with pheochromocytoma. Am J Hypertens. 2000;13(1 Pt 1):35–43.CrossRefPubMed Noshiro T, Shimizu K, Watanabe T, Akama H, Shibukawa S, Miura W, et al. Changes in clinical features and long-term prognosis in patients with pheochromocytoma. Am J Hypertens. 2000;13(1 Pt 1):35–43.CrossRefPubMed
41.
go back to reference Goldstein RE, O’Neill Jr JA, Holcomb 3rd GW, Morgan 3rd WM, Neblett 3rd WW, Oates JA, et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg. 1999;229(6):755–64. discussion 764–6.CrossRefPubMedPubMedCentral Goldstein RE, O’Neill Jr JA, Holcomb 3rd GW, Morgan 3rd WM, Neblett 3rd WW, Oates JA, et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg. 1999;229(6):755–64. discussion 764–6.CrossRefPubMedPubMedCentral
42.
go back to reference Khorram-Manesh A, Ahlman H, Nilsson O, Friberg P, Odén A, Stenström G, et al. Long-term outcome of a large series of patients surgically treated for pheochromocytoma. J Intern Med. 2005;258:55–66.CrossRefPubMed Khorram-Manesh A, Ahlman H, Nilsson O, Friberg P, Odén A, Stenström G, et al. Long-term outcome of a large series of patients surgically treated for pheochromocytoma. J Intern Med. 2005;258:55–66.CrossRefPubMed
43.
go back to reference Sharma N, Kumari S, Jain S, Varma S. Pheochromocytoma: a 10-year experience in a tertiary care North Indian hospital. Indian Heart J. 2001;53(4):481–5.PubMed Sharma N, Kumari S, Jain S, Varma S. Pheochromocytoma: a 10-year experience in a tertiary care North Indian hospital. Indian Heart J. 2001;53(4):481–5.PubMed
44.
go back to reference Maskey P, Shrestha GK, Luitel BR, Gupta DK, Sidarth, Chalise PR, et al. Phaeochromocytoma in Nepal--a single centre experience. Kathmandu Univ Med J (KUMJ). 2012;10(39):52–5. Maskey P, Shrestha GK, Luitel BR, Gupta DK, Sidarth, Chalise PR, et al. Phaeochromocytoma in Nepal--a single centre experience. Kathmandu Univ Med J (KUMJ). 2012;10(39):52–5.
45.
go back to reference Yu R, Nissen NN, Chopra P, Dhall D, Phillips E, Wei M. Diagnosis and treatment of pheochromocytoma in an academic hospital from 1997 to 2007. Am J Med. 2009;122(1):85–95.CrossRefPubMed Yu R, Nissen NN, Chopra P, Dhall D, Phillips E, Wei M. Diagnosis and treatment of pheochromocytoma in an academic hospital from 1997 to 2007. Am J Med. 2009;122(1):85–95.CrossRefPubMed
46.
go back to reference Yu R, Wei M. False positive test results for pheochromocytoma from 2000 to 2008. Exp Clin Endocrinol Diabetes. 2010;118(9):577–85.CrossRefPubMed Yu R, Wei M. False positive test results for pheochromocytoma from 2000 to 2008. Exp Clin Endocrinol Diabetes. 2010;118(9):577–85.CrossRefPubMed
47.
go back to reference Baguet JP, Hammer L, Mazzuco TL, Chabre O, Mallion JM, Sturm N, et al. Circumstances of discovery of pheochromocytoma: a retrospective study of 41 consecutive patients. Eur J Endocrinol. 2004;150(5):681–6.CrossRefPubMed Baguet JP, Hammer L, Mazzuco TL, Chabre O, Mallion JM, Sturm N, et al. Circumstances of discovery of pheochromocytoma: a retrospective study of 41 consecutive patients. Eur J Endocrinol. 2004;150(5):681–6.CrossRefPubMed
48.
go back to reference Amar L, Servais A, Gimenez-Roqueplo AP, Zinzindohoue F, Chatellier G, Plouin PF. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab. 2005;90(4):2110–6. Epub 2005 Jan 11.CrossRefPubMed Amar L, Servais A, Gimenez-Roqueplo AP, Zinzindohoue F, Chatellier G, Plouin PF. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab. 2005;90(4):2110–6. Epub 2005 Jan 11.CrossRefPubMed
Metadata
Title
Does this patient have pheochromocytoma? A systematic review of clinical signs and symptoms
Authors
M. Pourian
Davani B. Mostafazadeh
A. Soltani
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2015
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1186/s40200-016-0230-1

Other articles of this Issue 1/2015

Journal of Diabetes & Metabolic Disorders 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.